中国循证医学杂志

中国循证医学杂志

中国肝癌筛查卫生经济学研究的系统评价

查看全文

目的系统评价中国人群肝癌筛查卫生经济学研究现状,为后续进一步开展相关研究提供依据。方法计算机检索 PubMed、EMbase、The Cochrane Library、Web of Science、CNKI、WanFang Data、CBM 和 VIP 数据库,搜集我国人群肝癌筛查卫生经济学研究,检索时限均从建库至 2017 年 12 月 31 日。由 2 位研究者独立筛选文献、提取资料,对纳入研究基本特征、卫生经济学评价方法及主要结果等进行描述性分析,并对研究质量及报告规范性进行评价。结果共纳入 5 个研究。纳入研究的肝癌筛查起始年龄在 35~45 岁,筛查技术多选用甲胎蛋白(AFP)联合超声,频率以每半年 1 次居多。5 个研究整体质量尚可;整体报告规范性尚可,得分中位数为 78%(60%,78%)。2 个研究报道了基于每检出 1 例肝癌的成本,分别为 4.4 万元和 57.5 万元。3 个研究报道了基于挽救生命年(LYS)和质量调整生命年(QALY)的成本-效果比(CER)指标,仅 1 个中国内地研究报道了每挽救一个 LYS 的成本,为 1 775 元,其与当地人均国内生产总值(GDP)比值为 0.1;另 2 个我国台湾地区的研究报道了 4 组筛查的成本-效果比,其与当地人均 GDP 比值范围为 1.0~2.2。结论肝癌高发地区我国台湾地区研究提示在普通人群中开展肝癌筛查经济有效;而我国大陆研究提示在高危人群中开展 AFP 联合超声筛查经济有效,但仅有 1 个地区性研究支持,仍需更多基于随机对照试验或队列研究的卫生经济学评价予以验证。

ObjectiveTo systematically review the status of economic evaluation of liver cancer screening in China, so as to provide reference for further studies.MethodsPubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data, CBM and VIP databases were searched to collect economic evaluation studies of liver cancer screening in China from inception to December, 2017. Two reviewers independently screened literature, extracted data and conducted descriptive analysis of basic characteristics, methods of economic evaluation and main results as well as quality and uniformity of reporting.ResultsA total of 5 studies were included. Among them, the starting age of screening were found to be 35 to 45 years old; α-fetoprotein (AFP) testing and ultrasound examination combined procedure and screening interval of every 6 months were mostly evaluated. The quality of the 5 studies was satisfactory, and the uniformity of reporting was relatively acceptable, with a median score of 78% (range: 60% ~ 78%). Two population-based studies reported cost per liver cancer detected (44 thousand and 575 thousand yuan). Three studies reported cost-effectiveness ratio(CER) based on life year saved (LYS) and quality adjusted life year (QALY). Among these results, only 1 study from mainland China reported CER based on LYS (1 775 yuan), and the calculated ratio of CER to local GDP per capita was estimated as 0.1, while 2 studies from Taiwan province reported 4 CERs, and the ratios of CER to local GDP per capita ranged from 1.0 to 2.2.ConclusionsInformation from liver cancer endemic areas such as Taiwan province indicates promising cost-effectiveness to conduct liver cancer screening in local general population, while data from mainland suggests that conducting liver cancer screening combining AFP and ultrasound in high-risk population will be cost-effective, however only supported by 1 regional study. This needs to be verified by further economic evaluations based on randomized controlled trials or cohort studies as well as health economic evaluations.

关键词: 肝癌; 筛查; 卫生经济学评价; 成本-效果分析; 系统评价; 中国

Key words: Liver cancer; Screening; Health economic evaluation; Cost-effectiveness analysis; Systematic review; China

引用本文: 白方舟, 王乐, 王宇婷, 黄慧瑶, 刘成成, 朱娟, 任建松, 赵建军, 韩优莉, 曲春枫, 代敏, 石菊芳. 中国肝癌筛查卫生经济学研究的系统评价. 中国循证医学杂志, 2018, 18(5): 442-449. doi: 10.7507/1672-2531.201802028 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. 陈万青, 孙可欣, 郑荣寿, 等. 2014 年中国分地区恶性肿瘤发病和死亡分析. 中国肿瘤, 2018, 27(1): 1-14.
2. 冉建朝, 王乐, 张玥, 等. 中国人群肝癌所致 DALY 疾病负担: 1990~2016 年长期分析及预测. 中国循证医学杂志, 2018, 18(5): 401-409.
3. Qiu WQ, Shi JF, Guo LW, et al. Medical expenditure for liver cancer in urban China: A 10‐year multicenter retrospective survey (2002-2011). J Cancer Res Ther, 2018, 14(1): 163-170.
4. 杨骏, 王乐, 石春雷, 等. 我国 1996-2015 年间肝癌经济负担研究系统评价. 中国疾病控制杂志, 2017, 21(8): 835-851.
5. 石菊芳, 石春雷, 岳馨培, 等. 1996-2014 年中国恶性肿瘤经济负担的系统评价. 中华肿瘤杂志, 2016, 38(12): 929-941.
6. 张业繁, 郭兰伟, 白方舟, 等. 我国肝癌住院患者 2002-2011 年日均医疗费用趋势分析: 多中心回顾性调查. 中国循证医学杂志, 2018, 18(5): 434-441.
7. Allemani C, Matsuda T, Carlo VD, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
8. Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. Plos Med, 2014, 11(12): e1001774.
9. Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology, 2010, 51(2): 405-414.
10. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen, 2003, 10(4): 204-209.
11. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol, 2004, 130(7): 417-422.
12. 卫生部疾病预防控制局癌症早诊早治项目专家委员会. 癌症早诊早治项目技术方案 (2011 年版). 北京: 人民卫生出版社, 2011.
13. 代敏, 石菊芳, 李霓. 中国城市癌症早诊早治项目设计及预期目标. 中华预防医学杂志, 2013, 47(2): 179-182.
14. 李顺平, 马东平, 王健. 我国乙肝疫苗接种策略的经济学评价系统综述. 中国卫生经济, 2011, 30(3): 84-86.
15. 杨思嘉, 董红军. 新生儿乙肝疫苗接种卫生经济学评价方法研究进展. 浙江预防医学, 2013, 25(6): 29-32.
16. 石菊芳, 赵琨, 曲春枫, 等. 肝癌筛查相关卫生技术评估. 中国循证医学杂志, 2018, 18(5): 397-400.
17. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005.
18. Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health, 2013, 16(2): 231-250.
19. World Health Organization.Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
20. 中华人民共和国国家统计局. 中国统计年鉴. Available at: http://www.stats.gov.cn/tjsj/ndsj/.
21. 张博恒, 杨秉辉. 原发性肝癌筛查的成本效果分析. 中国临床医学, 1999, 6(2): 106-108.
22. 邱永莉, 王春芳, 顾凯, 等. 2002~2005 年上海市社区肝癌高危人群筛检成本效果分析. 上海预防医学杂志, 2006, 18(11): 533-535.
23. Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc, 2010, 109(1): 39-55.
24. 全文, 俞霞, 吴标华, 等. 鼻咽癌和肝癌联合筛查的流行病学及卫生经济学研究. 中山大学学报(医学科学版), 2014, 35(4): 614-618.
25. Kuo MJ, Chen HH, Chen CL, et al. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol, 2016, 22(12): 3460-3470.
26. Cucchetti A, Cescon M, Erroi V, et al. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol, 2013, 27(6): 961-972.
27. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics, 1998, 13(4): 397-409.
28. 刘国恩. 中国药物经济学评价指南及导读(2015 版). 北京: 科学出版社, 2015.
29. 张博恒, 杨秉辉. 甲胎蛋白联合实时超声检查作为肝癌筛查试验的评价. 中华医学杂志, 1999, 79(11): 844-845.
30. 黄慧瑶, 石菊芳, 代敏. 中国大肠癌筛查的卫生经济学评价研究进展. 中华预防医学杂志, 2015, 49(8): 747-751.
31. 王乐, 石菊芳, 黄慧瑶, 等. 我国乳腺癌筛查卫生经济学研究的系统评价. 中华流行病学杂志, 2016, 37(12): 1662-1669.
32. Institute for Health Metrics and Evaluation, University of Washington. GHDx. 2018. Available at: http://ghdx. healthdata.org/gbd-results-tool/.